Anhui Huaheng Biotechnology Co., Ltd. (SHSE:688639) Just Recorded An Earnings Miss And Analysts Are Updating Their Numbers
Anhui Huaheng Biotechnology Co., Ltd. (SHSE:688639) Just Recorded An Earnings Miss And Analysts Are Updating Their Numbers
Anhui Huaheng Biotechnology Co., Ltd. (SHSE:688639) just released its latest second-quarter report and things are not looking great. Anhui Huaheng Biotechnology delivered a grave earnings miss, with both revenues (CN¥515m) and statutory earnings per share (CN¥0.40) falling badly short of analyst expectations. Earnings are an important time for investors, as they can track a company's performance, look at what the analysts are forecasting for next year, and see if there's been a change in sentiment towards the company. So we gathered the latest post-earnings forecasts to see what estimates suggest is in store for next year.
安徽华恒生物技术股份有限公司(SHSE: 688639)刚刚发布了最新的第二季度报告,情况不容乐观。安徽华恒生物技术的收入(5.15亿元人民币)和每股收益(0.40元人民币)都大大低于分析师预期,表现糟糕。盈利报告对投资者来说是重要的时刻,可以追踪公司的表现,查看分析师对明年的预测,并观察市场对该公司的情绪是否发生变化。因此,我们收集了最新的盈利后预测,看看未来一年的预期。
![1724971983054](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240830/43089362-0-959116956db1704b80a422d6adf3b0d7.webp/bigjpg)
Following the latest results, Anhui Huaheng Biotechnology's seven analysts are now forecasting revenues of CN¥2.82b in 2024. This would be a substantial 34% improvement in revenue compared to the last 12 months. Per-share earnings are expected to accumulate 5.1% to CN¥1.88. Before this earnings report, the analysts had been forecasting revenues of CN¥3.17b and earnings per share (EPS) of CN¥2.77 in 2024. It looks like sentiment has declined substantially in the aftermath of these results, with a real cut to revenue estimates and a pretty serious reduction to earnings per share numbers as well.
根据最新的结果,安徽华恒生物技术的七位分析师预计2024年的收入将达到282亿元人民币。这将是过去12个月中营收大幅增长34%。预计每股收益将累积增长5.1%至1.88元人民币。在此盈利报告之前,分析师们预测2024年的收入为317亿元人民币,每股收益为2.77元人民币。看起来市场情绪在这些结果的影响下大幅下降,收入预测受到明显减少,并且每股收益也大幅减少。
The consensus price target fell 23% to CN¥71.99, with the weaker earnings outlook clearly leading valuation estimates. Fixating on a single price target can be unwise though, since the consensus target is effectively the average of analyst price targets. As a result, some investors like to look at the range of estimates to see if there are any diverging opinions on the company's valuation. Currently, the most bullish analyst values Anhui Huaheng Biotechnology at CN¥96.55 per share, while the most bearish prices it at CN¥43.56. This is a fairly broad spread of estimates, suggesting that analysts are forecasting a wide range of possible outcomes for the business.
共识价格目标下调23%至71.99元人民币,明显受到较弱的盈利前景的影响。但是,仅固定在一个价格目标上可能不明智,因为共识目标实际上是分析师价格目标的平均值。因此,一些投资者喜欢查看估计范围,以了解公司估值是否存在分歧意见。目前,最看好的分析师将安徽华恒生物技术的估值设定为96.55元人民币每股,而最看淡的则将其定价为43.56元人民币。这是一个相当广泛的估计范围,表明分析师对该企业的未来走势有着广泛的预期。
Of course, another way to look at these forecasts is to place them into context against the industry itself. It's clear from the latest estimates that Anhui Huaheng Biotechnology's rate of growth is expected to accelerate meaningfully, with the forecast 79% annualised revenue growth to the end of 2024 noticeably faster than its historical growth of 37% p.a. over the past three years. By contrast, our data suggests that other companies (with analyst coverage) in a similar industry are forecast to grow their revenue at 15% per year. Factoring in the forecast acceleration in revenue, it's pretty clear that Anhui Huaheng Biotechnology is expected to grow much faster than its industry.
当然,审视这些预测的另一种方式是将它们与行业本身的情况联系起来。从最新的估算结果来看,预计安徽华恒生物技术的增长率将加速,预计到2024年年化营业收入增长率将达到79%,明显快于过去三年的历史增长37%。相比之下,我们的数据表明,预计类似行业(受到分析师覆盖)的其他公司将以每年15%的速度增长营业收入。考虑到营业收入的预测加速,很明显安徽华恒生物技术的增长速度预计将远远快于其所在的行业。
The Bottom Line
最重要的事情是分析师增加了它对下一年每股亏损的估计。令人欣慰的是,营收预测未发生重大变化,业务仍有望比整个行业增长更快。共识价格目标稳定在28.50美元,最新估计不足以对价格目标产生影响。
The biggest concern is that the analysts reduced their earnings per share estimates, suggesting business headwinds could lay ahead for Anhui Huaheng Biotechnology. They also downgraded Anhui Huaheng Biotechnology's revenue estimates, but industry data suggests that it is expected to grow faster than the wider industry. The consensus price target fell measurably, with the analysts seemingly not reassured by the latest results, leading to a lower estimate of Anhui Huaheng Biotechnology's future valuation.
最大的担忧是分析师们下调了每股收益的预估,表明安徽华恒生物技术可能面临业务上的逆风。他们还下调了安徽华恒生物技术的营业收入预估,但行业数据显示预计其增长速度将快于更广泛的行业。共识价值目标明显下降,分析师似乎对最新的结果不感到放心,导致对安徽华恒生物技术未来估值的预期降低。
Keeping that in mind, we still think that the longer term trajectory of the business is much more important for investors to consider. We have estimates - from multiple Anhui Huaheng Biotechnology analysts - going out to 2026, and you can see them free on our platform here.
记住,我们仍然认为业务的长期轨迹对于投资者来说更为重要。我们有多位安徽华恒生物技术分析师的估算,覆盖到2026年,你可以在我们的平台上免费查看。
Don't forget that there may still be risks. For instance, we've identified 3 warning signs for Anhui Huaheng Biotechnology (2 can't be ignored) you should be aware of.
不要忘记,可能仍然存在风险。例如,我们已经找到了安徽华恒生物技术的3个警示信号(其中2个不容忽视),你应该注意。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对本文有任何反馈?对内容有任何疑虑?请直接与我们联系。或者,发送电子邮件至editorial-team@simplywallst.com。
这篇文章是Simply Wall St的一般性文章。我们根据历史数据和分析师预测提供评论,只使用公正的方法论,我们的文章并不意味着提供任何金融建议。文章不构成买卖任何股票的建议,也不考虑您的目标或您的财务状况。我们的目标是带给您基本数据驱动的长期关注分析。请注意,我们的分析可能不考虑最新的价格敏感公司公告或定性材料。Simply Wall St没有任何股票头寸。